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Abstract Five molecular subtypes (luminal A, luminal
B, HER2-enriched, basal-like, and claudin-low) with clin-
ical implications exist in breast cancer. Here, we evaluated
the molecular and phenotypic relationships of (1) a large
in vitro panel of human breast cancer cell lines (BCCLs),
human mammary fibroblasts (HMFs), and human mam-
mary epithelial cells (HMECs); (2) in vivo breast tumors;
(3) normal breast cell subpopulations; (4) human embry-
onic stem cells (hESCs); and (5) bone marrow-derived
mesenchymal stem cells (hMSC). First, by integrating
genomic data of 337 breast tumor samples with 93 cell
lines we were able to identify all the intrinsic tumor sub-
types in the cell lines, except for luminal A. Secondly, we
observed that the cell lines recapitulate the differentiation
hierarchy detected in the normal mammary gland, with
claudin-low BCCLs and HMFs cells showing a stromal
phenotype, HMECs showing a mammary stem cell/bipo-
tent progenitor phenotype, basal-like cells showing a
luminal progenitor phenotype, and luminal B cell lines
showing a mature luminal phenotype. Thirdly, we identi-
fied basal-like and highly migratory claudin-low subpop-
ulations of cells within a subset of triple-negative BCCLs
(SUM149PT, HCC1143, and HCC38). Interestingly, both
subpopulations within SUM149PT were enriched for
tumor-initiating cells, but the basal-like subpopulation
grew tumors faster than the claudin-low subpopulation.
Finally, claudin-low BCCLs resembled the phenotype of
hMSCs, whereas hESCs cells showed an epithelial phe-
notype without basal or luminal differentiation. The results
presented here help to improve our understanding of the
wide range of breast cancer cell line models through the
appropriate pairing of cell lines with relevant in vivo tumor
and normal cell counterparts.
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Introduction
Global messenger RNA expression analyses of human
breast cancers have established five ‘‘intrinsic’’ molecular
subtypes: luminal A, luminal B, basal-like, HER2-enri-
ched, and the recently characterized claudin-low group [1].
These molecular entities have shown significant differ-
ences in incidence, survival, and responsiveness to thera-
pies [1–4], and their information complements and expands
the information provided by the classical clinical–patho-
logical markers [5–8]. Importantly, studies focused on
intrinsic molecular subtyping are improving our under-
standing of the biologic heterogeneity of breast cancer and
its developmental cell(s) of origin [1, 9–11].
Although, the ideal preclinical study should be performed
with human tumor samples that represent the complete
spectrum of the disease, this type of research is being ham-
pered, in part, by the lack of appropriate in vivo assays.
Complementary to this approach are in vitro studies focused
on tumor- or normal tissue-derived cell lines, all of which are
being extensively used by the breast cancer research com-
munity [12]. Many of these cell lines have served as model
systems to either dissect the biology of breast cancer and/or
develop novel treatment strategies that are further tested in
patients. In some cases, these studies have led to improve-
ments for cancer patients. For example, the estrogen receptor
(ER)-positive MCF-7 cell line has been useful for the study of
the estrogen pathway and the development of efficacious anti-
hormonal therapies such as tamoxifen [13, 14], while HER2-
amplified SKBR3 and BT474 cell lines have helped to elu-
cidate various mechanisms of resistance to anti-HER2 ther-
apies [15, 16]. However, these preclinical studies have had
limited impact in the management of breast cancer patients
[17, 18], partly due to the incomplete understanding of the
similarities and differences between these in vitro model
systems and their relevant in vivo tumor counterparts.
Previous work has shown that the main genetic and
transcriptional features of breast tumors are present in cell
lines [19–22]. In 2006, Neve et al. [19] identified two major
groups (basal and luminal) in a panel of *50 breast cancer
cell lines by independently comparing the global expres-
sion profiles of cell lines and primary breast tumors.
Interestingly, the basal cluster was further subdivided into
two subgroups: basal-A, which resembled the basal-like
signature in primary breast tumors [2, 3] and basal-B,
which exhibited a mesenchymal and a cancer stem cell
(CSC)-like profile that was less similar to primary basal-
like tumors. The identification of the basal-B group has
been confirmed by three other groups [21–23], with one
group calling them normal-like [23]. More recently, we and
others have shown that a subgroup of 9 (MDA-MB231,
SUM159PT, MDA-MB157, BT549, SUM1315MO2,
MDA-MB436, MDA-MB435, HBL100 and Hs578T) of
the 12 basal-B breast cancer cell lines best resemble the
recently characterized claudin-low tumor subtype [1, 24].
However, it is still unknown if all the intrinsic subtypes are
represented in cell lines.
In the human mammary gland, four subpopulations of
cells have been identified and functionally characterized
[9]. By utilizing a combination of fluorescence-activated
cell sorting (FACS) with EpCAM and CD49f cell surface
markers and a series of in vitro and in vivo experiments,
Lim et al. [9] observed that the normal breast tissues have
at least four subpopulations enriched with mammary stem
cells/bipotent progenitors (MaSC/BiPs), luminal progeni-
tors (pLs), mature luminal cells (mLs), and stromal cells
(after excluding lineage positive cells, i.e., lymphocytes,
red blood and endothelial cells). Using Lim et al.’s [9] gene
expression data, we subsequently reported a differentiation
model that tracks the epithelial differentiation hierarchy
(MaSC/BiP ? pL ? mL) and is prognostically relevant.
More importantly, we showed that the tumor intrinsic
subtypes recapitulate the normal breast epithelial differ-
entiation hierarchy, where claudin-low tumors and cell
lines are the most similar to the MaSC/BiPs [1, 10]. These
and other findings have led to new hypotheses regarding
the potential cell of origin and/or transformation of the
different breast cancer subtypes [10, 25, 26]. However, it is
unknown where other cell lines, including normal human
mammary epithelial cells (HMECs), fall into this hierar-
chy. Still less is known about the relationship of adult
human mesenchymal stem cells (hMSCs) and embryonic
stem cells (hESCs) to different breast tumor subtypes and
cell lines.
In this report, we evaluated a large in vitro panel of
breast cell lines and compared their features with (1)
tumors, (2) four cell subpopulations of the normal breast,
and (3) hMSC and hESC. Specifically, we show that all of
the tumor subtypes except the luminal A and normal
breast-like are well represented in cell lines. In addition, we
observed that the cell lines recapitulate many of the fea-
tures of each normal breast cell subpopulation identified
using FACS.
Results
Molecular comparison between cell lines and breast
samples
To compare the global gene expression profiles of cell lines
with in vivo breast samples, we profiled a panel of in vitro
breast cancer cell lines (BCCLs), human mammary fibro-
blasts (HMFs), and HMECs, and combined the microarray
data (UNC105, GSE50470) with our previously published
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UNC337 data set that is composed of 320 breast tumors and
17 normal breast samples (GSE18229) [1]. In this combined
data set (Fig. 1a), the gene expression loading plot of the
principal components 1 (PC1) and 2 (PC2) discriminate the
tumor intrinsic subtypes with the vast majority of cell lines
being displayed toward high PC1. Interestingly, we found
Fig. 1 Combined gene expression data of cell lines, breast tumors
and normal breast samples. a Principal component (PC) 1 and 2
loading plots and their correlation with proliferation and differenti-
ation scores, respectively. Samples included here were the entire
UNC337 data set and all the UNC breast cancer cell lines (UNC105).
b Euclidean distance of selected UNC cell lines to the UNC337 tumor
intrinsic subtypes, including the claudin-low tumor type. c Differen-
tiation and d proliferation scores of the tumor (left) and cell lines
(right) grouped by their molecular subtype. Cells derived from normal
breast tissue are shown in the following categories: HMF, HMECs
and immortalized HMECs (I-HMECs). Subtype calls: luminal A (LA)
dark blue; luminal B (LB) light blue; HER2-enriched (H2) pink;
basal-like (BL) red; claudin-low (CL) yellowish; normal breast-like
(NBL) green; cell line gray. Replicate arrays done in the same cell
line have been omitted, prioritizing first the UNC samples followed
by the Neve et al. samples when appropriate
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PC1 to be correlated with expression of proliferation-
related genes (r2 = 0.634, p \ 0.0001), while PC2 was
highly correlated to our previously described differentia-
tion genomic model (MaSC/BiP ? pL ? mL axis) [1]
(r2 = 0.908, p \ 0.0001). Thus, this data suggests that the
majority of gene expression variation occurring in breast
tumors and normal samples is explained by two variables
(1) differentiation status along a MaSC/BiP ? pL ? mL
axis and (2) proliferation.
To determine which intrinsic molecular profile each cell
line best resembles, we calculated the distances of each cell
line to the luminal A, luminal B, basal-like, HER2-enri-
ched tumor centroids, and the normal breast-like group in
the combined tumor-cell line data set; we also applied the
9-cell line claudin-low predictor to identify claudin-low
cell lines. As shown in Fig. 1b and Supplemental material,
all the intrinsic molecular subtypes were identified in
tumor- and normal breast-derived cell lines except for the
luminal A subtype and the normal breast-like group.
Interestingly, all HMFs were identified as claudin-low,
whereas HMECs were called either basal-like (i.e., HMLE,
HMECBX) or claudin-low (i.e., ME16C, HMECA1).
However, all HMECs showed borderline significance (i.e.
ratios close to 1.0) for being identified as claudin-low, thus
suggesting that these normal cell-type lines have mixed
claudin-low/basal-like characteristics.
We then combined our cell line-tumor data set with
three previously published cell line data sets [19, 21, 22]
for a total of 93 different microarrays of cell lines. As
expected, we observed the same findings; namely, no cell
line was identified as luminal A or normal breast-like.
However, among the 52 cell lines evaluated with at least
one replicate sample among the four data sets, seven
(13 %) discrepancies in the subtype calls were observed.
Nonetheless, these data highlight that in virtually all cases,
breast cancer cell lines maintain their overall genomic
profile even if cultured in different laboratories and assayed
on different platforms.
We have previously shown that BCCLs can be dis-
criminated by their differentiation status along a MaSC/
BiP ? pL ? mL axis [1]. To determine if this is also
valid when a larger panel of cell lines is evaluated together
with in vivo breast samples, we determined the differen-
tiation scores of the combined tumor and cell line data set.
Interestingly, we observed that the cell lines recapitulate all
the differentiation states observed in tumors (Fig. 1c),
which is consistent with the fact that we observed all of the
molecular subtypes in cell lines (except for the luminal A
and the normal breast-like). As previously reported and as
shown in Fig. 1c, luminal A and B tumors are indistin-
guishable based on their differentiation score status,
whereas proliferation (i.e., PC2) is one of the main dif-
ferences between them (Fig. 1d). Evaluation of the
proliferation status revealed that BCCLs show higher
expression of proliferation-related genes compared to their
in vivo tumor subtype counterpart (Fig. 1d, p \ 0.0001,
Student t test). As expected, primary HMECs and HMFs
showed lower expression of proliferation-related genes
compared to BCCLs, although still higher than luminal A
tumors.
Finally, to further understand the differences between
tumors and cell lines, we identified those genes that are
either up- or down-regulated in all cell lines when com-
pared to their respective tumor counterpart (Supplemental
material). As expected, the down-regulated cell line spe-
cific genes (n = 244) were mainly involved in immune
response (i.e., lymphocyte antigen 96 and adenosine
deaminase) and extracellular matrix (i.e., adrenomedullin),
concordant with a lack of lymphocytic and stromal com-
ponents in these in vitro cultures. Interestingly, removing
these potential cell-type or heterotypic interaction specific
genes from the tumor and cell line combined data set did
not substantially affect the differentiation status of the
tumors (Supplemental material), suggesting that the dif-
ferentiation predictor is mainly tracking the in vivo biology
of the tumor epithelial cells themselves.
Characterization of stromal and epithelial FACS
subpopulations of the normal breast
To understand the relationship between cell lines and the
different subpopulations of the normal breast, we FAC-
sorted and expression-profiled stromal, MaSC/BiP, pL, and
mL subpopulations from at least three independent reduc-
tion mammoplasties as previously described by Lim et al.
[9] (Fig. 2a). As shown in Fig. 2b and Supplemental
material, *35 and *25 % of lineage-negative cells (i.e.,
CD45-negative and/or CD31-negative) fall in the stromal-
and MaSC/BiP-enriched groups, respectively, whereas
only *10 % of the cells are identified in the pL and mL-
enriched groups. To further complement these results, we
also analyzed six independent reduction mammoplasties
using CD24 and CD44 cell surface markers. As shown in
Fig. 2c, 50, 22, and 4.6 % of the sorted cells were CD24-/
CD44?, CD24-/CD44-, and CD24?/CD44? in one sam-
ple. However, the CD24?/CD44? subpopulation was not
always identified (data not shown).
Our previously described differentiation score predictor
was based on genomic data of the MaSC/BiP-, pL- and
mL-enriched subpopulations of Lim’s et al. [9] (i.e.,
training set). To validate this differentiation model, we
estimated the differentiation status of our newly sorted cell
subpopulations (Fig. 2d). As expected, the MaSC/BiPs
showed the lowest scores (mean -0.350 ± 0.047), the
mLs showed the highest scores (mean 0.625 ± 0.0328),
and the pLs showed a slightly higher differentiation status
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(0.16 ± 0.0237) than Lim’s pL (trained to be zero).
Overall, high correlation coefficients ([0.90, p \ 0.0001)
between EpCAM and CD49f gene and protein expression
was observed in the four normal-sorted fractions (Sup-
plemental material).
To further characterize the four normal breast FACS
subpopulations, including the three CD24/CD44-sorted
fractions, we evaluated the expression of markers associ-
ated with epithelial and luminal differentiation, epithelial-
to-mesenchymal transition and stem cell and/or tumor-
Fig. 2 Characterization of mesenchymal and epithelial subpopula-
tions of the normal breast. a Diagram summarizing the processing and
steps taken for FACS of normal breast tissue. b, c Distribution of the
lineage-negative cell subpopulations in one representative reduction
mammoplasty sample using EpCAM/CD49f and CD24/CD44 surface
markers. d Differentiation score of the four-sorted cell subpopulations
of at least three reduction mammoplasties samples. p values shown
here have been calculated by comparing gene expression means
across all subpopulations. e Supervised hierarchical clustering of the
sorted subpopulations based on the expression of a panel of markers
of basal and luminal differentiation, EMT and CSCs markers. Each
colored square of the heatmap represents the relative transcript
abundance (in log 2 space) for each cell fraction with highest
expression being red, average expression being black, and lowest
expression being green. Keratins 5 [KRT5], 14 [KRT14] and 17
[KRT17], 18 [KRT18] and 19 [KRT19]); ER (ESR1); progesterone
receptor (PGR); HER2 (ERBB2); vimentin [VIM]; snail-1 [SNAI1];
snail-2 [SNAI2]; Zinc finger E-box homeobox 1 and 2 [ZEB1 and
ZEB2]; E-cadherin [CDH1]; Claudins -3 [CLDN3], -4 [CLDN4]
and -7 [CLDN7]); prominin 1 [CD133]; epithelial cell-adhesion
molecule [EpCAM]; mucin 1 [MUC1]; integrin alpha 6 [CD49f];
integrin beta 1 [CD29]; membrane metallo-endopeptidase [CD10];
aldehyde dehydrogenase family 1, subfamily A1 [ALDH1A1]. f,
g Immunofluorescent staining of the four breast cell subpopulations
and normal breast ducts using antibodies against vimentin (green),
keratin 5 (red) and keratin 8 (green)
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initiating cells (TIC) as described in Prat et al. [1]. As
observed (Fig. 2e) hierarchical clustering of the FAC-sor-
ted samples with these selected gene expression values
revealed three main groups: stromal, MaSC/BiP, and pL/
mL. Interestingly, the MaSC/BiP-enriched subpopulation is
characterized by (1) the highest expression of basal kera-
tins (KRT17, KRT14 and KRT5) and CD49f compared to
the other subpopulations (p \ 0.0001, Student’s t test), and
(2) a lower expression of luminal keratins and epithelial
cell-adhesion genes such as CLDN7 and CDH1 compared
to the pL- and mL-enriched subpopulations (p \ 0.0001,
Student’s t test). Interestingly, the CD24-/CD44? and
CD24-/CD44- cell fractions clustered with the MaSC/
BiP-enriched group, while the CD24?/CD44? subpopula-
tion clustered with the pL/mL subpopulations, suggesting
that a greater homogeneity can be obtained with CD49f/
EpCAM combination of markers. Finally, the stromal-
enriched subpopulation showed a lack of expression of
epithelial markers and cell–cell-adhesion genes, with high
expression of stromal markers (i.e., vimentin) and tran-
scription factors such as ZEB1 and SNAI2.
Further analyses of four normal breast FACS subpopu-
lations by immunofluorescent (IF) staining with antibodies
against basal (KRT5), luminal (KRT8), and stromal (VIM)
markers confirmed these findings (Fig. 2f), although cer-
tain heterogeneity within each sorted subpopulation was
also observed. Finally, IF imaging of normal breast ducts
revealed that the majority of cells within the stromal-
enriched group (VIM?/KRT5-/KRT8-) are found in the
stroma, the MaSC/BiP-enriched cells (VIM?/KRT5?/
KRT8-) are found in the basal/myoepithelial layer and,
finally, the pL (VIM-/KRT5?/KRT8?) and mL (VIM-/
KRT5-/KRT8?) cells are found in the luminal layer of the
duct (Fig. 2g).
Cell lines recapitulate the differentiation hierarchy
of the normal breast
To determine the transcriptomic similarities between the
normal breast subpopulations (stromal, MaSC/BiP, pL,
and mL) and cell lines in 2D culture, including HMFs and
HMECs, we first calculated a signature enrichment score
for each of the centroids using the Lim et al. [9] micro-
array data, and we included in this analysis our normal
breast-sorted fractions as controls. As shown in Fig. 3a,
HMFs showed the highest enrichment for the stromal
signature suggesting that the vast majority of sorted Ep-
CAM-CD49f-/low cells from normal breast tissue are
indeed fibroblasts. On the other hand, the MaSC/BiP
signature was found almost uniquely enriched in HMECs.
We identified 1,530 genes that are similarly expressed
between HMECs and MaSC/BiPs [significance analyses of
microarrays (SAM) one-class, FDR = 0 %; Supplemental
material]. Among the up-regulated genes, we observed
basal keratins 5/14/17, p63, CD49f, and CD44. Conversely,
claudin-low cell lines showed an intermediate differentia-
tion status between the MaSC/BiP and the stromal state.
This is consistent with our previous report showing that,
compared to basal-like and luminal BCCLs, claudin-low
BCLLs are closer to the MaSC/BiP centroid than to the pL
or mL centroids [1]. However, here we show that the
claudin-low cells are uniquely enriched with stromal-like
biological processes similar to HMFs. Both the stromal
fraction of the normal breast and claudin-low BCCLs were
found to share similar expression of 1,334 genes (SAM one-
class, FDR = 0 %; Supplemental material). Among the
1,097 down-regulated genes, we observed genes associated
with cell–cell adhesion (i.e., Claudin -3, E-cadherin, and
desmoplakin), epithelial markers (EPCAM and CD24), and
markers of luminal differentiation (GATA3, FOXA1 and
keratins -8, -18, and -19). Finally, basal-like and luminal
B BCCL genomic profiles showed to be the closest to the pL
and mL centroids, respectively, whereas the differentiation
status of the HER2-enriched cell lines was found to be
between the pL and mL state.
To characterize cell lines from a phenotypic perspective,
we performed FACS on a panel of 30 cell lines, repre-
senting all the molecular subtypes using established stem
and/or CSC surface markers including EpCAM, CD49f,
CD24, and CD44. As shown in Fig. 3b and in Supple-
mental data, claudin-low cell lines and HMFs express a
stromal/MaSC phenotype with the majority of cells within
these cell lines being EpCAM-/low/CD49f? and CD24-/
low/CD44?. Conversely, all of the evaluated HMECs,
regardless if they were immortalized or not, showed a
MaSC/BiP phenotypic profile (EpCAM-/low/CD49fhigh),
which is consistent with the gene expression data. In terms
of proposed CSC markers, HMECs showed a non-CSC
phenotype (CD24?/CD44?); except for cells from the
immortalized ME16C cell line that showed a CD24-/
CD44? phenotype. Moreover, the majority of cells within
most basal-like cell lines showed a pL/mL and a non-CSC
phenotypes (EpCAM?/CD49f? and CD24?/CD44?), and
the vast majority of luminal B and HER2-enriched cell
lines also showed a pL-mL and a non-CSC phenotypes.
However, it is important to note that FACS alone did not
fully discriminate basal-like from luminal/HER2-enriched
cell lines, since CD49f levels were variable.
Finally, we performed IF staining analysis of cell lines
using the same stromal and epithelial markers as previously
done for the normal breast. As shown in Fig. 3c and Sup-
plemental material, all claudin-low cell lines showed strong
membrane staining for vimentin and little to no keratin 5 and
8 positivity (i.e., MDA-MB231, SUM159PT) similar to
HMFs, or keratin 5-positivity only (i.e., HCC38, HCC1395).
The majority of basal-like cell lines, however, contained a
242 Breast Cancer Res Treat (2013) 142:237–255
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mixed population of cells where some had only basal keratin
positivity and others had dual basal/luminal keratin posi-
tivity. However, none of these basal-like cells showed
strong vimentin positivity, concordant with their epithelial
state. Furthermore, luminal B and HER2-enriched cell lines
showed strong positivity for luminal keratin 8 and the
majority had no vimentin or keratin 5 staining; exceptions
include the HER2-enriched cell lines BT474 and SKBR3
and luminal B cell line HCC1500 that showed some
expression of keratin 5. Finally, we observed that the pri-
mary and immortalized HMECs showed strong positivity
for keratin 5, positivity for vimentin, and varying degrees of
keratin 8 protein expression, concordant with a partial epi-
thelial-to-mesenchymal state in these cells similar to the one
observed in the MaSC/BiP (EpCAM?/CD49f?) FACS
subpopulation.
Distinct subpopulations of cells within Claudin-low
and basal-like cell lines
Among the cell lines evaluated, SUM149PT (basal-like),
HCC1143 (basal-like), and HCC38 (claudin-low) showed
two clear separate cell subpopulations based on the levels of
EpCAM and CD49f surface markers (Fig. 4a). As we
Fig. 3 Cell lines recapitulate the differentiation hierarchy of the
normal breast. a Enrichment scores of Lim’s stromal, MaSC/BiP, pL,
and mL gene signatures in BCCLs grouped by their molecular
subtypes, HMFs, HMECs, and our normal breast FAC-sorted
subpopulations. *p value \ 0.05, **p value \ 0.001. Replicate arrays
done in the same cell line have been omitted, prioritizing first the
UNC samples followed by the Neve et al. samples when appropriate.
Signature enrichment scores for each Lim et al. fraction (stromal,
MaSC/BiP, pL and mL) has been obtained by calculating the distance
of each cell line to two Lim et al. centroids: ‘‘others’’ versus ‘‘each
Lim et al. fraction’’. In the plot, the ratio of the ‘‘others’’ distance
versus ‘‘each Lim et al. fraction’’ distance is shown. b EpCAM/CD49f
and CD24/CD44 FACS of claudin-low (Hs578T), HMEC
(HMECBL), basal-like cell line (HCC1187) and luminal B
(HCC1428) cell lines. c IF staining of Hs578T, HMECBL,
HCC1187 and HCC1428 cell lines using antibodies against vimentin
(green), keratin 5 (red) and keratin 8 (green). The complete FACS
and IF staining data of all cell lines evaluated can be obtained in
Supplemental material
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previously reported for the SUM149PT cell line [1], molec-
ular subtyping of the EpCAM-/low/CD49f? and EpCAM?/
CD49f?-sorted fractions of HCC38 and HCC1143 cell lines
confirmed that they are claudin-low and basal-like, respec-
tively. Intriguingly, we could not identify these subpopula-
tions of cells using CD24/CD44 surface markers. All
HCC1143 cells showed high levels of the luminal marker
CD24 when compared to SUM149PT and HCC38, where the
majority of cells showed a CD24-/low/CD44? phenotype
(Fig. 4b).
To identify potential genes and/or biological processes
responsible for the two states of differentiation in SUM149PT,
HCC1143, and HCC38 cell lines, we performed a paired two-
class SAM analysis between the EpCAM-/low/CD49f? and
EpCAM?/CD49f?-sorted fractions within each cell line, and
identified the overlapping genes across all three cell lines. As
shown in Fig. 4c, the numbers of up- and down-regulated
genes appearing in all comparisons exceeded the chance of
overlap expected (P \ 0.0001, exact hypergeometric proba-
bility). Among them, we observed high expression in the
EpCAM-/low/CD49f? fraction of genes involved in
‘‘response to wounding’’ (adrenomedullin and chemokine [C-
X-C motif] ligand 1), ‘‘extracellular matrix’’ (collagen, type
V, alpha 1, and laminin, gamma 1), and ‘‘migration’’ (inter-
leukin 6 and fibronectin 1). Conversely, we observed low
expression in the EpCAM-/low/CD49f? fraction of genes
involved in tight junction (Claudin 3, 4, and 7 and par-6 par-
titioning defective 6 homolog alpha) and keratinization (ker-
atins 14, 15, 16, 19).
Consistent with these findings, EpCAM-/low/CD49f?
fractions from the three cell lines showed increased in vitro
transwell migration, and HCC1143 and HCC38 EpCAM-/
low/CD49f? showed lower protein expression of keratins
and higher vimentin expression compared to their respec-
tive EpCAM?/CD49f? cells (Fig. 5a–c and Supplemental
material). Interestingly, decreased proliferation during
5 days of growth was observed in the EpCAM-/low cells
compared to their respective EpCAM? fractions (Fig. 5d)
and this is similar to comparisons of human claudin-low
tumors versus basal-like [1].
Finally, when EpCAM-/low/CD49f? and EpCAM?/
CD49f? subpopulations within HCC1143 cell lines were
sorted and plated separately, we observed that *25 % of
the EpCAM-/low/CD49f? cells differentiated into Ep-
CAM?/CD49f? basal-like cells over a 14–18 day period,
whereas the EpCAM?/CD49f? basal-like cells seem to
maintain their differentiated status during in vitro culture
(Fig. 5e), similar to our previous findings in SUM149PT
[1]. Interestingly, the majority of HCC38 EpCAM-/low/
CD49f? cells remained HCC38 EpCAM-/low/CD49f?
during the same period of time, concordant with decrease
in asymmetric division and an overall claudin-low profile
identified in this cell line.
Tumor initiating cell ability of the two cell
subpopulations within SUM149PT cell line and basal-
like xenograft WashU-WHIM2
To explore the TIC ability of the two subpopulation of cells
in the SUM149PT cell line, we FAC-sorted EpCAM-/low/
CD49f? and EpCAM?/CD49f? cells (Fig. 6a) and injected
different numbers of cells (100, 1,000, and 10,000 cells) of
each subpopulation into nude immunocompromised mice.
Interestingly, the distinct fractions could not be determined
by CD24/CD44 staining (Fig. 6b), despite the fact that the
EpCAM-/low/CD49f? fraction showed the expected stromal
phenotype (Fig. 6c). The in vivo experiment revealed that
over long-term growth conditions ([100 days), both frac-
tions were enriched with TICs. However, the TICs in the
EpCAM?/CD49f? fraction grew tumors significantly faster
than the TICs in the claudin-low fraction (p \ 0.0001 at the
60 days’ time-point, extreme limiting dilution analysis
(ELDA) [27]; Fig. 6d, e). Thus, if a 1 month time-point was
used, only the EpCAM?/CD49f? fraction would be con-
sidered a TIC-containing fraction. Nearly identical results
were obtained for EpCAM/CD49f FAC sort of the human
triple-negative WashU-WHIM2 xenograft, which has been
whole genome sequenced [28]. One notable difference
between SUM149PT and the WashU-WHIM2 FACS profile
was that in the latter no distinct cell subpopulations were
found, instead a more homogeneous oval-shaped profile was
seen (Fig. 6f). Similar findings were obtained when the two
populations of WashU-WHIM2 FACS were compared;
namely that the EpCAM?/CD49f?/high population was the
TIC-enriched fraction (p = 0.0136, ELDA; Fig. 6g) and
showed stronger basal gene expression characteristics (data
not shown). Thus, overall, both in a cell line and in a
xenograft tumor, the TIC component was the highly pro-
liferative and more basal-like EpCAM?/CD49f? cells.
Fig. 4 Genomic analyses of distinct cell subpopulations within basal-
like and claudin-low cell lines. a Expression of EpCAM/CD49f in
HCC1143 (basal-like), SUM149PT (basal-like) and HCC38 (claudin-
low) cell lines. The gates shown in each cell line (gray squares)
represent the different sorted subpopulations that were further
evaluated. b Expression of CD24/CD44 in the three cell lines. The
colors represent the distribution of the sorted fractions in (a).
c Overlap of genes differentially expressed between EpCAM-/low/
CD49f? and EpCAM?/CD49f? cells across HCC1143, SUM149PT
and HCC38. p values denote the probability of the overlap being by
chance. Below each Venn diagram, the up- and down-regulated gene
ontology (GO) terms are shown. Each list included the genes that
overlapped between at least two cell fractions (red or green genes).
d Supervised hierarchical clustering of the sorted subpopulations
based on the expression of the differentially expressed genes between
EpCAM-/CD49f? and EpCAM?/CD49f? cells across HCC1143,
SUM149PT and HCC38. On the right, relative expression data in
hESC cells that have acquired a mesodermal state. All the gene lists
and the clustering can be obtained in Supplemental material
b
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HMECs as model systems for the study of the Claudin-
low transformation
Human mammary epithelial cells have been used as model
systems to study the CSC transformation in breast cancer
[29–32] and our FACS and IF analyses presented here
point to a MaSC/BiP-state and a non-CSC phenotype in
these cells. To better understand the features of the trans-
formation of HMECs, we first expression profiled the
previously published HMLE cell line (a non-transfected
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immortalized HMEC) and its two stem cell-like HMLE
counterparts (coming from the same source) where
TWIST1 and SNAI1 had been artificially induced, and are
tumorigenic in nude mice by introduction of an activated
form of the HER2/neu oncogene [30]. While the HMLE
cell line showed the expected antigenic and gene expres-
sion MaSC/BiP phenotype, induction of a stem cell phe-
notype in HMLE cell line by expression of TWIST1 or
SNAIL1 resembled a MaSC/BiP ? stromal differentiation
direction with acquisition of a claudin-low profile and
phenotype (EpCAM-/CD49f?) together with an increased
expression of vimentin and decreased expression of keratin
8 (Fig. 7 and Supplemental material).
Claudin-low/stromal cells resemble the hMSC
phenotype
Recent reports have implicated hMSCs and/or hESCs and
their biological processes in the development and/or pro-
gression of breast cancer [33–36]. To gain further insight
into the relationship of hMSC and hESC with breast-
derived cell lines, we characterized and expression profiled
a panel of three hMSC and two hESC cell lines. In terms of
antigenic phenotype, all three hMSC cell lines showed a
stromal (EpCAM-/CD49flow) and a CSC (CD24-/CD44?)
phenotype (Supplemental material), while the two hESC
lines showed a luminal progenitor (EpCAM?/CD49f?) and
a non-stem cell phenotypes of CD24?/CD44?. Concordant
with the FACS data, hMSCs were vimentin-positive and
keratin -5 and -8 negative, whereas hESCs were found
negative for all three markers. More importantly, gene
expression analyses revealed that the hMSCs cluster with
claudin-low BCCLs and HMFs, while the two hESCs
cluster as its own group, but closest to the epithelial
basal-like and luminal/HER2-enriched subtypes (Fig. 7).
Intrinsic molecular subtyping revealed that the hMSCs
and hESC are identified as claudin-low and basal-like,
respectively. Finally, we observed that the core gene
expression signature obtained by comparing the EpCAM?
(basal-like) and EpCAM- (claudin-low) cell fractions of
the HCC38, SUM149PT, and HCC1143 cell lines resem-
bles a previously published gene expression pattern of
hESC cells after differentiating into the mesodermal line-
age (i.e., hMSCs) [37] (Fig. 4d).
Summary of the characterization of cell lines
A summary of the phenotypic and molecular data of all cell
lines derived from breast cancers and normal mammary
tissues evaluated in this study is provided (Fig. 8).
Discussion
In this report, we have characterized the phenotypic and
molecular features of a large panel of cell lines derived
from breast cancers and normal mammary tissues, and we
have linked these features with the intrinsic subtypes of
breast tumors, FACS enriched cell subpopulations of the
normal mammary gland, and two types of true stem cells.
Specifically, we made the following observations: (1)
BCCLs in general resemble all the intrinsic subtypes of
breast cancer except for luminal A, (2) BCCLs recapitulate
all the differentiation statuses observed in the normal breast
with HMECs best resembling the MaSC/BiP-enriched
subpopulation, (3) subpopulations of cells with claudin-low
and basal-like features are typically found within the subset
of triple-negative cancer cell lines with overall basal-like
features, and (4) within these mixed basal-like cell lines (or
primary tumor xenografts WashU-WHIM2) the EpCAM?/
CD49f? cells are more proliferative and more tumorigenic
than the Claudin-low-like EpCAM-/CD49f? fraction,
which is more motile.
Established in vitro breast cancer cell lines are being
extensively used by the research community to address
various aspects of cancer biology [12, 38–40]. Our data
indicate that cell lines do recapitulate most of the differ-
entiation states observed in breast cancer; however, we did
not identify cell lines that resemble the good prognosis
luminal A tumor type, which is the most frequent subtype
identified in breast cancer [1–4]. One potential explanation
for this finding is that the vast majority of luminal cell lines
have been derived from metastatic tumor samples, such as
pleural effusions (i.e., MCF7, T47D) or ascites (i.e., ZR75-
1), therefore, introducing a selection bias toward more
aggressive subtypes, such as those observed in the poor
prognostic luminal B subtype. In addition, 2D in vitro
assay itself and/or the media conditions used for cell cul-
ture might be a harsh environment for luminal A-like cells
which is also reflected by the fact that despite the
Fig. 5 Functional analyses of distinct cell subpopulations within
basal-like and claudin-low cell lines. a, b Trans-well migration
capability of the EpCAM-/low/CD49f? and EpCAM?/CD49f? cell
fractions within each cell line. Microscopic image (920) of migrated
cells (underside of the membrane) within HCC1143-sorted fractions
stained with 0.2 % crystal violet. Migration was quantified by
measuring the optical density of the eluted crystal violet solubilized
with 100 ll of methanol. c Dual keratin 5/keratin 8 and vimentin IF
imaging of HCC1143-sorted fractions. d Proliferation status of the
different sorted fractions during cell culture after FACS. Proliferation
was estimated by recording the absorbance at 490 nm of the MTS-
PES compound in each time point. e, f In vitro differentiation of
EpCAM-/low/CD49f? HCC1143 and HCC38 cells. The two-sorted
cell subpopulations from each cell line were grown in vitro under the
same conditions as before FACS. After 14–18 days in culture,
expression of CD49 and EpCAM was reanalyzed in both subpopu-
lations using FACS
b
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observation that 10 % of lineage-negative cells in the
normal breast FACS experiments are mL or pL. However,
none of these cells could be readily identified in our 2D
cultures of primary HMECs. In fact, the percentage of
success of obtaining a cell line from ER? primary tumors
has been reported to be\10 % [41, 42]. This suggests that
only cells with low adherence, high proliferation, and
migration capabilities are more likely to be selected for
further passage, thus precluding the establishment of low
proliferative and highly adherent luminal A/mL cells. This
hypothesis could explain why among the 65 BCCLs eval-
uated, 66 % (43/65) are ER-negative, which is clearly not
representative of the subtype incidence in patients.
The overall gene expression profiles of the cell lines that
technically overlapped (n = 52) across four independent
cell line data sets were highly similar. However, seven
Fig. 6 TIC experiments in SUM149PT cell line and WashU-
WHIM2. a FAC-sorted plot based on EpCAM and CD49f expression.
Red color: basal-like; yellowish color: Claudin-low. b FAC-sorted
plot based on CD24 and CD44 expression. Red and yellowish colors
identify the population of cells identified in the EpCAM/CD49f plot.
c Dual keratin 5/keratin 8 and keratin 5/vimentin IF imaging of
SUM149PT-sorted fractions. d TIC experiment for both sorted
fractions. e Luciferase imaging of tumors in nude mice (n = 2 for
each fraction) 19 days after injecting 1,000 cells. f Expression of
EpCAM/CD49f and identification of two different cell fractions
within the WashU WHIM2 model: CD49Flow and CD49Fhigh.
g Tumor-initiating ability of the two-sorted fractions in (f), and
expression of EpCAM/CD49f of the resulting tumors
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(13 %) discrepancies were noted. Most of these discrep-
ancies occurred in cell lines whose gene expression profiles
were found borderline between two subtypes, except for
HCC1500 cell line (Supplemental material). For example,
ER-negative/HER2-negative MDA-MB468 cell line is
basal-like in two data sets (Hollestelle et al. [21] and
UNC105), and shows borderline significance for HER2-
enriched in the other two data sets, while ER-positive/
HER2-amplified BT474 is called HER2-enriched in three
data sets and luminal B in Kao et al. [22]. This finding
could be explained by the specific genotypic/phenotypic
features of these cell lines that are also observed in the two
subtypes. For example, BT474 is a known ER?/HER2-
amplified cell line [43, 44]; while MDA-MB468 is a ER-
negative/HER2-negative cell line with EGFR amplification
[45], which might activate, in part, the HER2 pathway as in
a HER2-amplified tumor.
The cell line data presented here also support our previ-
ously reported relationship between the basal-like and the
claudin-low phenotypes [1]. Namely, we observed that the
three ER-negative/HER2-negative cell lines classified as
basal-like (HCC1143, SUM149PT) or claudin-low (HCC38)
have basal-like and claudin-low subpopulations of cells
within them, albeit with different proportions. Besides,
similar to EpCAM-/low/CD49f? cells in SUM149PT [1],
claudin-low EpCAM-/low/CD49f? cells from HCC1143 cell
Fig. 7 Characterization of hMSC and hESC. Unsupervised hierar-
chical clustering of cell lines using the most variable genes
(n = 17,824). Expression of selected genes is shown in the heatmap.
Each colored square of the heatmap represents the relative transcript
abundance (in log 2 space) for each cell fraction with highest
expression being red, average expression being black, and lowest
expression being green
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lines can differentiate and give rise to basal-like EpCAM?/
CD49f? cells. In vivo, tumors obtained from the EpCAM-/
low and EpCAM?/high fractions show a FACS profile similar
to the starting cell line (or tumor for WashU-WHIM2). Thus,
even when only EpCAM-/low claudin-low-like cells are
used, the natural state and balance are re-established both
in vitro and in vivo.
Furthermore, we have shown that despite expressing
different levels of surface markers CD44 and CD24, the
gene expression differences between EpCAM-/low/CD49f?
versus EpCAM?/CD49f? cells within each cell line are
highly similar across all the three cell lines, suggesting that
the similar biological events (e.g., migration capability) are
occurring between these two fractions. However, it is
important to note that we did not evaluate other stem cell or
TIC markers such as ALDH1 [46], and that the Matrigel
used during the xenotransplantation assay can influence the
properties of stem cells and TICs [47, 48]. In any case,
recent RNAi knockdown experiments in the SUM149PT
cell line have identified Smarcd3/Baf60c, and thus the
SWI/SNF chromatin-remodeling complex, as a key medi-
ator of this EMT by activating WNT signaling pathways
[49].
Human epithelial cell lines derived from normal breast
tissue are being extensively used by the research commu-
nity either as primary cells or after immortalization by
exogenous hTERT transduction [30, 50, 51]. Although,
speculation of their basal origin and MaSC/BiP capacity
has been previously suggested by others [51], no study to
the best of our knowledge has specifically addressed to
which epithelial cell-type these cell lines best resemble.
Using a genomic, FACS and IF staining analyses with
luminal, basal and mesenchymal markers, we observed that
both immortalized and primary HMECs in the pre-stasis
stage [52] resemble a phenotype similar to the MaSC/BiPs-
enriched subpopulation as defined by Lim et al. [9]. Indeed,
we observed that the vast majority of cells within HMECs
express high levels of basal keratin 5 and are vimentin-
positive. This is concordant with our data and Lim et al.’s
[9] data showing that the highest percentage of keratin 5
and vimentin positivity is observed in the MaSC/BiP sub-
population. On the other hand, when compared to tumors,
HMECs showed a differentiation state between the clau-
din-low and the basal-like tumor subtype, concordant
overall with a simultaneous mesenchymal and basal state
within these cells.
We and others have previously shown that the claudin-
low tumors and cell lines are enriched for CSC biological
processes [1, 53–56]. In this report, we have observed that
although this subtype is more similar to the MaSC/BiP-
enriched subpopulation than the other breast cancer sub-
types, claudin-low cell lines show a loss of epithelial
markers with acquisition of a stromal state that also
resembles the stromal-enriched subpopulation (i.e., fibro-
blasts) as defined by Lim et al. [9]. This is concordant with
the seminal article by Mani et al. [30] showing that the
acquisition of a full epithelial-to-mesenchymal transition
after transfecting EMT-inducing transcription factors
TWIST1 or SNAI1 into an immortalized HMEC increases
the self-renewal capacity (a feature of stemness [51]) of the
cells, and when transformed with KRAS oncogene allows
to form tumors more efficiently in nude mice. In this report,
using the same cell line variants developed by Mani et al.
[30], together with a combination of genomics and EpCAM
Fig. 8 Summary of the characterization of cell lines derived from
breast cancers and normal mammary tissues for the study of the
intrinsic subtypes. a IF staining for vimentin, keratin 5 and keratin 8
proteins. b Tumor molecular subtypes that each cell line best
resemble. c Cell-type of each cell line. d Approximate localization of
Lim et al.’s gene expression profiles of each normal breast
subpopulations. e Approximate genomic expression landscape of
human embryonic and mesenchymal stem cell profiles. f Approximate
genomic expression landscape of the mesenchymal and epithelial
profiles
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and CD49f surface markers, we have shown that this
mesenchymal transformation actually resembles a MaSC/
BiP ? stromal direction. Nonetheless, Battula et al. [34]
have further characterized these EMT-derived HMECs and
have shown that these cells are similar to bone marrow-
derived mesenchymal stem cells with the capacity to dif-
ferentiate into multiple tissue lineages such as osteoblasts,
chondrocytes, and adipocytes. Intriguingly, transformation
into tissue types other than the ones found in the mammary
gland, such as, bone or cartilage is also observed in
metaplastic tumors [57, 58], a rare histological type of
breast cancer associated with poor prognosis and enriched
for CSC/claudin-low profiles [56, 59]. Overall, these data
suggest that the acquisition of a full mesenchymal state
induces a multi-potent state more similar to mesenchymal
stem cells than the more restricted MaSC/BiP, which seem
to be in a partial mesenchymal and basal state. Thus,
claudin-low tumors and cell lines might have an origin in a
yet unidentified cell-type that is less differentiated than the
MaSC/BiP-enriched subpopulation as defined in Lim et al.
[9]. Conversely, the cell of origin of claudin-low and basal-
like tumors could still be a MaSC/BiP phenotype, featuring
various degrees of the EMT induction with claudin-low
cells going to the full EMT state. Alternatively, the cell of
origin of claudin-low tumors could be a highly undiffer-
entiated normal cell that already expresses these stromal
features, thus without the need for an EMT transition.
Further studies that combine molecular profiling and line-
age tracing experiments are needed to determine the cell of
origin of each subtype.
To conclude, the integration of global gene expression
data of cell lines with tumors and normal cell subpopula-
tions is a novel strategy and could be used in other tumor
types since it allows determining objectively which tumor
or cell-type each cell line best resembles. The results pre-
sented here should also help to improve our understanding
of the widely used encyclopedia of breast cell line models,
and provide more precise tools for the study of breast
cancers.
Materials and methods
UNC human breast tumor and cell line microarray data
sets
For human tumor and normal tissue samples, we used all
the microarrays and clinical data from Prat et al. (UNC337,
GSE18229) [1]. For cell lines and sorted tissue, RNA was
purified using RNeasy Mini kit and profiled as described
previously using oligo microarrays (Agilent Technologies,
USA) [60]. All microarray cell line data has been deposited
in the Gene Expression Omnibus under the accession
number GSE50470 (referred to here as UNC105). The
probes or genes of the combined UNC337 and UNC105
data set for all analyses were filtered by requiring the
lowess normalized intensity values in both sample and
control to be [10. The normalized log 2 ratios (Cy5
sample/Cy3 control) of probes mapping to the same gene
(Entrez ID as defined by the manufacturer) were averaged
to generate independent expression estimates.
Integration of three independent cell line data sets
to the UNC337-UNC105 set
We used our cohort of cell lines (UNC105) and three
publicly available microarray cell line data from the fol-
lowing data sets: Neve et al. (http://icbp.lbl.gov/ccc/index.
php) [19], Hollestelle et al. (GSE16795) [21], and Kao
et al. (http://smd.stanford.edu/) [22]. For all publicly data
sets, raw data was normalized using the robust multi-array
analysis normalization approach. To integrate all the
datasets, we assumed that the five matched cell lines that
are common to all four cohorts were the same and thus
used them as controls. In supplemental material, a diagram
summarizes the different microarray data sets analyzed in
the different figures and the combination strategy for
molecular subtyping each cell line.
Intrinsic subtype classification of cell lines
For the basal-like, HER2-enriched, luminal A, luminal B,
and normal breast-like intrinsic subtype classification, we
calculated the distance of each cell line to each of the
tumor subtype centroids, and assigned a subtype call where
the lowest distance was identified. Next, claudin-low cell
lines were identified using the previously reported 9-cell
line claudin-low predictor [1]. Samples identified as clau-
din-low were called claudin-low regardless of the previous
subtype call. Euclidian distances and subtype calls for all
cell lines are provided in Supplemental data.
Breast cancer cell lines, and immortalized HMEC/
HMFs
SUM159PT (Asterand) and SUM1315O2 cells (Asterand)
were maintained in Ham’s F12 with 5 % fetal bovine
serum (FBS), insulin (5 lg/ml), hydrocortisone (1 lg/ml,
SUM159PT-only), and EGF (10 ng/ml, SUM1315O2-
only). MCF-7, BT474, SKBR3, HCC1428, HCC1187,
HCC1143, BT549, HCC1395, HCC38, UAC893, ZR75-1,
HCC1500, T47D, and HCC1937 were cultured in RPMI
with 10 % FBS [61]. SUM149PT was maintained in Hu-
MEC media with supplements (Gibco) with 5 % FBS [62].
MDA-MB231, Hs578T, and MDA-MB436 were cultured
in DMEM (high glucose) with 10 % FBS. HME-CC
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(BABE) [61], SUM102PT, HMLE, HMLE-SNAI1,
HMLE-TWIST1, and HME31-hTERT no. 16C (ME16C)
[61] were cultured in HuMEC media with supplements
(Gibco). MDA-MB468 was cultured in Leibovitz’s L-15
medium with 10 % FBS. HMLE, HMLE-SNAI1, and
HMLE-TWIST1 cell lines were a kind gift of Sendurai A.
Mani (University of Texas M.D. Anderson Cancer Center).
An immortalized human mammary fibroblast cell line
(called here HMF4) was a kind gift of Charlotte Kuper-
wasser (Tufts University School of Medicine). All cell
lines were grown at 37 C and 5 % carbon dioxide, and
were obtained from the American Type Culture Collection
unless otherwise specified. We also obtained total RNA
from the following collaborators: Jeffrey M. Rosen and
Rachel Schiff (Baylor College of Medicine; MCF10A,
MDAMB415, MDAMB435, MDAMB134; BT483,
CAMA1, UACC812, ZR75B); Ned Sharpless (UNC;
UACC893); Sendurai A. Mani and Wendy Woodward
(University of Texas M.D. Anderson Cancer Center;
MCF12A, MCF12F, MDAIBC3, SUM190PT).
Mammary tissue and xenograft tumor tissue
preparations
Fresh human normal breast tissues from five reduction
mammoplasties were obtained using Institutional Review
Board approved protocols. Unless otherwise stated, all
reagents were from Stem Cell Technologies. Samples were
minced and digested at 37 C for 16 h in DMEM/F12
(GIBCO #11330) containing 0.5 lg/ml hydrocortisone,
5 lg/ml insulin, and 19 collagenase/hyaluronidase
(#07912). Xenograft tumor tissues were dissociated for 2 h.
The pellet from digested tissue was resuspended by
pipetting for 5 min in warm 0.05 % trypsin–EDTA (GIB-
CO # 25300054) followed by addition of 1:10 mixture of
DNase I (#07900), and Dispase (#07923). Red blood cells
were removed by lysis in 1:4 mixture of cold Hanks’ bal-
anced salt solution (#37150) containing 2 % FBS (HF) and
0.8 % ammonium chloride solution (#07850). Cells were
resuspended in HF and filtered through a 40 lm cell
strainer (BD Falcon #352340) to obtain single cell
suspensions.
Isolation of primary HMECs
Tissue obtained from four reduction mammoplasties were
processed to obtain organoids. For this purpose dissociated
tissue, as described above, were passed through 40 lm cell
strainers. Organoids were collected from the top of the
strainers using HMEC culture media, plated in 2D cultures
and maintained in HuMEC media with supplements (Gib-
co). RNA was purified from all primary HMECs before
passage 3 (pre-stasis stage) [52]. We also obtained total
RNA of four primary HMECs isolated by Pilar Blancafort
(UNC; HMECPB1, HMECPB2, HMECPB3, HMECPB4)
[63].
Isolation of primary HMFs
Single cells suspensions obtained from dissociation of three
independent reduction mammoplasties as described above
were cultured in DMEM/F-12 medium with 10 % FBS.
hESC and hMSCs
Two independent NIH hESC cell lines (H9 and H7) were
obtained from the University of North Carolina Embryonic
Stem Cell Core directed by B. Matthew Fagan. Commer-
cially available hMSCs were purchased from Millipore,
PromoCell, and Lonza.
Flow cytometry
Cells obtained from dissociated normal or tumor tissue, or
trypsinized cell lines were counted, washed with HF, and
stained for 30 min at 4 C with antibodies specific for
human cell surface markers from BD Pharmingen, except
otherwise noted: EpCAM-FITC (Stem Cell Technologies,
#10109), CD49f-PE-Cy5, (#551129), CD24-PE (#555428),
CD44-APC (#559942), CD31-FITC (#555445), and CD45-
FITC(#555482). Cells were washed from unbound anti-
bodies and immediately analyzed using Beckman-Coulter
(Dako) CyAn ADP or sorted using iCyt Reflection instru-
ment. Cell viability was determined by using either blue-
fluorescent reactive dye (Molecular Probes #L23105) or
7AAD (Molecular Probes #A1310). Dead cells and cells
positive for lineage markers CD31 and CD45 were
removed during sorting experiments. RNA was purified
from sorted cells using RNeasy Mini kit (Qiagen).
Cell proliferation assay
Thousand cells from each sorted fraction were plated in 36
wells of a 96-well plate. At each time point, 20 ll of MTS-
PES reagent was added in each well as provided in the
CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, USA), and we recorded its absorbance at
490 nm after 1 h of incubation. Three replicates for each
time point and cell line were measured.
Immunofluorescence
Cell lines and normal breasts were processed using standard
immunofluorescence staining methods as previously
described [4]. The primary antibodies and their dilution were
anti-vimentin (mouse anti-human IgG1-Kappa, dilution
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1:100; Invitrogen/Zymed), anti-cytokeratin 5 (rabbit anti-
human/mouse, dilution 1:50; Abcam, #ab24647), anti-
cytokeratin 8 (CAM 5.2, mouse anti-human, dilution 1:2;
Becton–Dickinson, #349205 and Zymed 18-0213, mono-
clonal, dilution 1:50).
TIC experiments
Luciferase stable SUM149PT cell line and tumors obtained
from WashU-WHIM2 xenograft model were FAC sorted
into subpopulations based on EpCAM and CD49F
expression as described earlier. FAC-sorted cell fractions
were placed on HuMEC media with supplements, 5 % FBS
and 5 % MatrigelTM. For SUM149PT cell line, three dif-
ferent aliquots containing 100, 1,000, and 10,000 cells
were injected into five nude mice each. Tumor volume was
measured every 5–7 days by caliper in two dimensions.
Experiments were done in triplicate. For the WashU-
WHIM2 model, 250,000 cells of each fraction were
injected in 4 NOD scid gamma mice.
Statistical analyses
Biologic analysis of microarray data was performed with
DAVID annotation tool (http://david.abcc.ncifcrf.gov/)
[64. SAM was performed in Excel as previously described)
[1]. ANOVA, Student’s t tests, and exact hypergeometric
probability for gene expression data and Pearson correla-
tion for protein–gene expression were performed using R
(http://cran.r-project.org). Reported p are two-sided.
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